Insulin lispro


Thông tin thuốc gốc
Chỉ định và Liều dùng
Parenteral
Diabetes mellitus
Adult: Dosage is individualised and adjusted according to patient's metabolic requirement, blood glucose level, and glycaemic control goal. Generally used in combination with intermediate- or long-acting insulin. Dosage adjustments may be necessary when switching from another insulin, during acute illness, or with changes in physical activity, meal patterns, renal or hepatic function, or concurrent medications. Doses may be given via SC inj or continuous SC insulin infusion (CSII). Additionally, may be given via IV administration when necessary, using appropriate preparation for IV use. Refer to specific product or local treatment guidelines for further information.
Child: Treatment recommendations may vary among individual products and countries (refer to specific product or local treatment guidelines).
Suy thận
Dosage adjustment may be required.
Suy gan
Dosage adjustment may be required.
Cách dùng
Should be taken with food. Administer w/in 15 min before or immediately after meals.
Chống chỉ định
Hypersensitivity. Episodes of hypoglycaemia.
Thận trọng
Patient at risk for hypokalaemia (e.g. receiving loop diuretics). Early warning symptoms of hypoglycaemia may be different or less pronounced in patients with long-standing diabetes, intensified insulin therapy, diabetic nerve disease, or in those who switched from animal-source insulin to human insulin. Renal and hepatic impairment. Children. Pregnancy and lactation. Concomitant use with peroxisome proliferator-activated receptor (PPAR)-γ agonists (including thiazolidinediones).
Tác dụng không mong muốn
Significant: Hypoglycaemia, hypokalaemia; lipodystrophy and cutaneous amyloidosis at the inj site.
Gastrointestinal disorders: Diarrhoea, nausea, abdominal pain.
General disorders and administration site conditions: Inj site reaction (e.g. redness, itching, swelling), flu-like symptoms, pain, oedema.
Immune system disorders: Antibody development.
Nervous system disorders: Headache.
Respiratory, thoracic and mediastinal disorders: Cough, nasopharyngitis, rhinitis, pharyngitis.
Potentially Fatal: Severe hypoglycaemia, hypersensitivity reactions (including anaphylaxis).
Thông tin tư vấn bệnh nhân
This drug may impair the ability to concentrate and react as a result of hypoglycaemia; if affected, do not drive or operate machinery.
Chỉ số theo dõi
Monitor blood glucose (usually before meals and snacks and at bedtime; additional monitoring if needed); electrolytes, HbA1c (at least twice yearly in patients who are meeting treatment goals and have stable glycaemic control; quarterly for those who are not meeting treatment goals or with change in therapy); renal and hepatic function, weight.
Quá liều
Symptoms: Hypoglycaemia associated with listlessness, confusion, sweating, vomiting, headache, palpitations. Management: Administer oral glucose, other sugar or saccharated products for mild hypoglycaemic episodes. In case of moderately severe hypoglycaemia, administer IM or SC glucagon followed by oral carbohydrate once the patient sufficiently recovers; administer IV glucose solution for those who do not respond to glucagon. Sustained intake of carbohydrates and observation may be needed.
Tương tác
May decrease efficacy with oral contraceptives, corticosteroids, β2 stimulants (e.g. ritodrine, terbutaline, salbutamol), thyroid hormones, danazol, diuretics, growth hormone. May increase risk of hypoglycaemia with other antidiabetic agents, salicylates (e.g. aspirin), sulfa antibiotics, certain ACE inhibitors (e.g. enalapril, captopril), angiotensin II receptor blockers, β-blockers, certain antidepressants (e.g. MAOIs, SSRIs), somatostatin analogues (e.g. octreotide). May cause dose-related fluid retention which may lead to or exacerbate cardiac failure with PPAR-γ agonists including thiazolidinediones (e.g. pioglitazone). Signs and symptoms of hypoglycaemia may be blunted by β-blockers.
Tương tác với thức ăn
May increase or decrease efficacy with alcohol.
Tác dụng
Description: Insulin lispro is a rapid-acting insulin analogue that regulates the metabolism of glucose by binding to insulin receptors. This action stimulates peripheral glucose uptake by the skeletal muscle and fat and inhibits hepatic glucose production, thus lowering blood glucose levels. It also inhibits proteolysis and lipolysis and enhances the synthesis of protein.
Onset: Approx 15 minutes (variable).
Duration: SC: 2-5 hours (variable).
Pharmacokinetics:
Absorption: Rapidly absorbed. Time to peak plasma concentration: Approx 30-70 minutes (SC).
Excretion: Via urine.
Đặc tính

Chemical Structure Image
Insulin lispro

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 16132438, Insulin lispro. https://pubchem.ncbi.nlm.nih.gov/compound/Insulin-lispro. Accessed Nov. 24, 2021.

Bảo quản
Unopened vial/cartridge/pen: Store between 2-8°C. Do not freeze. Protect from heat and light. Opened (in-use) vials: Store between 2-8°C or below 30°C for up to 28 days. Opened (in-use) cartridge/pen: Store below 30°C for up to 28 days. Do not freeze or refrigerate. Storage recommendations may vary among individual products. Refer to specific product guidelines.
Phân loại MIMS
Insulin
Phân loại ATC
A10AC04 - insulin lispro ; Belongs to the class of intermediate-acting insulins and analogues. Used in the treatment of diabetes.
A10AB04 - insulin lispro ; Belongs to the class of fast-acting insulins and analogues. Used in the treatment of diabetes.
Tài liệu tham khảo
Anon. Insulin Lispro. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 04/10/2021.

Anon. Insulin Lispro. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 08/10/2021.

Humalog 100 units/mL Junior KwikPen Solution for Injection in a Pre-Filled Pen (Eli Lilly Nederland B.V.). MHRA. https://products.mhra.gov.uk. Accessed 24/09/2021.

Humalog 100 units/mL KwikPen Solution for Injection in a Pre-Filled Pen (Eli Lilly Nederland B.V.). MHRA. https://products.mhra.gov.uk. Accessed 24/09/2021.

Humalog 100 units/mL Solution for Injection in Cartridge (Eli Lilly Nederland B.V.). MHRA. https://products.mhra.gov.uk. Accessed 24/09/2021.

Humalog 100 units/mL Solution for Injection in Vial (Eli Lilly Nederland B.V.). MHRA. https://products.mhra.gov.uk. Accessed 24/09/2021.

Humalog 100 units/mL Tempo Pen Solution for Injection in a Pre-Filled Pen (Eli Lilly Nederland B.V.). MHRA. https://products.mhra.gov.uk. Accessed 24/09/2021.

Humalog KwikPen 100 units/mL Solution for Injection (Eli Lilly [Philippines], Inc). MIMS Philippines. http://www.mims.com/philippines. Accessed 04/10/2021.

Humalog KwikPen Injection 3 mL (100 IU/mL), Solution for Injection in a Pre-Filled Pen (Zuellig Pharma Sdn Bhd). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 04/10/2021.

Humalog Kwikpen, Junior Kwikpen, Tempo Pen Injection Solution (Eli Lilly and Company). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 24/09/2021.

Joint Formulary Committee. Insulin Lispro. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 24/09/2021.

Lyumjev 100 units/mL Junior KwikPen Solution for Injection in Pre-Filled Pen (Eli Lilly Nederland B.V.). MHRA. https://products.mhra.gov.uk. Accessed 24/09/2021.

Lyumjev 100 units/mL KwikPen Solution for Injection in Pre-Filled Pen (Eli Lilly Nederland B.V.). https://products.mhra.gov.uk. Accessed 24/09/2021.

Lyumjev 100 units/mL Solution for Injection in Cartridge (Eli Lilly Nederland B.V.). MHRA. https://products.mhra.gov.uk. Accessed 24/09/2021.

Lyumjev 100 units/mL Solution for Injection in Vial (Eli Lilly Nederland B.V.). MHRA. https://products.mhra.gov.uk. Accessed 24/09/2021.

Lyumjev 200 units/mL KwikPen Solution for Injection in Pre-Filled Pen (Eli Lilly Nederland B.V.). MHRA. https://products.mhra.gov.uk. Accessed 24/09/2021.

Lyumjev Kwikpen, Junior Kwikpen, Tempo Pen, Injection Solution (Eli Lilly and Company). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 24/09/2021.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Insulin lispro từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2022 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in